Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco

MUMBAI - In a move that could have far-reaching impact in determining India's approach to compulsory licensing, Natco Pharma - the local oncology and anti-HIV drugs specialist - has written to German drugs-to-agrochemicals giant Bayer to provide it with a "voluntary license" to manufacture and market its anti-cancer drug brand Nexavar (sorafenib)

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip